



ASX ANNOUNCEMENT

12 September 2016

## ***Expiry of Unlisted Options***

Cynata Therapeutics Ltd (ASX: CYP) hereby advises that the following options expired on 9 September 2016:

<b>Code</b>	<b>Expiry Date</b>	<b>Exercise Price</b>	<b>Options</b>
CYPAK	09/09/2016	\$0.40	500,000

The total number of options remaining on issue is as follows:

<b>Code</b>	<b>Expiry Date</b>	<b>Exercise Price</b>	<b>Options</b>
CYPAI	27/09/2018	\$0.40	5,000,000
CYPAN	16/12/2018	\$0.49	750,000
CYPAM	22/02/2019	\$0.53	600,000
CYPAM	17/07/2020	\$1.00	3,666,669
			<b>10,016,669</b>

**Media contacts:** Dr Ross Macdonald, CEO: Tel: 0412 119343; email [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email [stewart.washer@cynata.com](mailto:stewart.washer@cynata.com)

### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ utilises induced pluripotent stem cells (iPSCs) to produce a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ platform provides a source of MSCs that is independent of donor limitations and provides an "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical product business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.